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Abstract 
Autologous adult stem cells (ASCs) are being administered by physicians for indications that 
have not been demonstrated as safe and effective in formal clinical trials. Examination of 
regulatory frameworks across five countries suggests that balancing the demands of 
research with clinical freedom has created structural weaknesses that are being exploited.  
Introduction 
Although well-supported clinical applications of stem cells remain relatively few in number 
(Daley, 2012), the use of ASCs in advance of evidence from clinical trials has become 
increasingly prevalent (Bianco, 2013). Once mostly limited to countries lacking the 
regulatory infrastructure needed to monitor and control the claims made by healthcare 
professionals and institutions operating within their borders (Kiatpongsan and Sipp, 2008), 
these practices have also emerged in places such as the United States, Australia and Japan 
(Lysaght et al., 2014). The global proliferation of these practices raises serious concerns 
about the exploitation of vulnerable patient populations, the regulation of novel cell-based 
therapeutics, and the governance of medical professionals.  
However, these practices appear less prevalent in some countries with similar standards in 
healthcare, scientific investment and economic structure to the US, Australia and Japan – 
Singapore and the United Kingdom are examples. This disparity suggests that there may be 
differences in the regulatory systems that oversee clinical uses of autologous ASCs in these 
countries that may be encouraging or discouraging their use outside the context of clinical 
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trials. To investigate this possibility, we compared the regulatory regimes of the United 
States, Japan, Australia, Singapore, and the United Kingdom (as a Member State of the 
European Union), with the aim of identifying similarities and differences in how autologous 
ASCs are regulated and governed within clinical contexts. We found that while there are 
many technical differences in language and implementation, broad similarities in the 
general regulatory approach suggest that there is no one explanation as to why these 
practices are more prevalent in some countries with apparently well-developed regulatory 
frameworks. 
Regulation of Stem Cells in Research 
All five countries examined have generally supportive environments for basic scientific 
research using stem cells, with some differences for lines derived from human embryos 
(Ishii et al., 2013). More importantly, they have all adopted risk-based approaches that 
regulate the use of stem cells in clinical research as either biological drug products or as 
medical procedures. In all of these countries, cell and tissue-based products (CTPs) that are 
regulated as drugs and/or biologics fall within the jurisdiction of a centralized government 
agency that controls the marketing of drugs, medical devices and biologics within each 
jurisdiction (listed in Table 1 along with relevant laws and regulations reviewed in this 
analysis). Such products are controlled through mandated premarket testing for safety and 
efficacy in specified indications, which typically involves a sponsor obtaining an 
Investigational New Drug (IND) designation and conducting a series of registered multiphase 
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(I–III) clinical trials. Subsequent market authorisation may include additional requirements 
for post-market surveillance.  
Yet, these requirements only apply to products that are assessed as having higher than 
minimal risks, the definition of which varies across jurisdictions. Each country has 
exemptions that exclude from regulation autologous cells that have not been manipulated 
extensively or combined with other articles, are intended for homologous use in functionally 
compatible tissues, and/or are harvested and transplanted as part of the same surgical 
procedure. For example, haematopoietic stem cell transplants using autologous grafts for 
the reconstitution of bone marrow function are not regulated as biological drugs in any of 
these jurisdictions. Details about the level of manipulation and intended use of the cells vary 
across jurisdictions, and the definitions used to describe these processes are often 
ambiguous or undefined, but there is a general consensus that such products do not pose 
serious safety problems and are thus subject to relatively limited regulatory oversight. 
However, what constitutes ‘homologous use’ is not clearly defined in any of the regulations 
(listed in Table 1) and examples of processes that constitute ‘non-substantial’ or ‘minimal’ 
manipulation, where stated, are not exhaustive and differ from country to country. 
Variations may therefore arise in which cells are classified as ‘minimal risk’ and which are 
categorized as requiring greater regulation in different countries.  
Even for highly manipulated products that are regulated as drugs, clinical trial sponsors and 
registered practitioners may apply to special programs that speed the approvals process or 
provide patients in exceptional circumstances with access to medicinal products that lack 
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the evidence necessary for market licensing. These programs differ in name and some of the 
conditions vary across jurisdictions. For example, so-called “compassionate use” or “special 
access” provisions, such as the Expanded Access Program in the US provide patients with 
access to experimental agents that are subject of an active IND, and personal importation 
policies such as the Named Patients Access program in Japan allow, in exceptional cases, 
importation for individual use of drugs that have been approved in another country. In 
contrast, no such restrictions apply for the Special Access Scheme in Australia, or the 
Specials Scheme and Hospital Exemption Scheme in the UK. Singapore does not have a 
formal access program but, as indicated below, registered practitioners operating in 
licensed hospitals may, at least in theory, offer unlicensed drugs to patients under their 
care.  
Regulation of Stem Cells in Clinical Practice 
The use of CTPs that are excluded from regulation as drugs (e.g. minimally manipulated 
autologous cells intended for homologous use), along with registered products that that are 
prescribed ‘off-license’ or ‘off-label’, are regulated as medical practice, rather than as 
medicinal products. In all five countries, the practice of medicine is not overseen by a 
central regulatory agency, but is regulated separately under complex frameworks of medical 
licensing boards, health departments and ministries, professional accreditation bodies, third 
party payers, and negligence laws (Taylor, 2010). Thus, while the laws around advertising 
medicines vary in each jurisdiction, practitioners may lawfully prescribe CTPs for indications 
that have not received pre-market approval within the discretion of their professional 
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judgment. Where an intervention falls outside the accepted standard of care, practitioners 
generally need adequate justification and may require special permission from an 
institutions’ clinical practice or governance board. If the intervention is prescribed as part of 
a research protocol, then they may also need approval from an institutional review board 
(IRB). However, no permission or oversight is required from the authorities that regulate the 
marketing of medicinal products in any of these jurisdictions.  
In addition, four of the five countries have laws that explicitly allow the manufacture of CTPs 
under the supervision of registered practitioners. In compliance with Article 3(7) of the 
Advanced Therapy Medicinal Products Directive (2001/83/EC) of the EU, the UK excludes 
from regulation any CTP that is “prepared on a non-routine basis” for use in a hospital under 
“the exclusive responsibility of a medical practitioner […] for an individual patient”. This 
‘hospital use exemption’ applies to other EU Member States, but has been implemented 
differently according to local interpretations of key terms, such as ‘non-routine’, leading to 
the exemption being applied more liberally in some countries (Mahalatchimy et al., 2012). 
The European Commission is thus currently considering the scope and application of the 
directive following public consultation in December 2012 (see web resources).  
The UK has also enabled the Specials Scheme under the Medicines Act (1968) and the 
Human Medicines Regulations (2012), which provides exceptions for medicinal products, 
including CTPs, that are manufactured under the supervision of a registered medical 
practitioner, or by external vendors under a ‘specials’ license that is obtained from the 
Medicines and Healthcare Products Regulatory Agency. Singapore has similar exemptions in 
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the Medicines Act (1975, revised 1985) for the preparation of medicinal products by or 
under the supervision of registered practitioners operating within hospitals licensed under 
the Private Hospitals and Medical Clinics Act (1980, revised 1999). In Australia, autologous 
cells that are manufactured and administered by a registered medical practitioner (or under 
their supervision) for a patient under their care are excluded from regulation under the 
Therapeutic Goods Act (1989) in the Therapeutic Goods (Excluded Goods) Order No. 1 of 
2011.  
In Japan, drugs that are administered within the scope of a ‘physician’s discretion’ in 
medical practice falls under the Medical Practitioners Law (1948) and are not regulated by 
the Pharmaceuticals and Medical Device Agency. Practitioners using autologous ASCs need 
to observe the Practice Notice: Conducting Regenerative and Cellular Medicine Using 
Autologous Cells and Tissue at Medical Institutions (2010), but this only requires approval 
from an internal review board. A new law is currently being proposed that will clarify the 
extent of freedom licensed physicians have to prescribe unlicensed CTPs within their 
'physicians discretion'. If enacted, medical institutions that offer these products will be 
required to register with the Ministry of Health, Labour and Welfare. However, following a 
risk-based approach, the law will only require full ministerial approval for pluripotent stem 
cells while IRB approval will suffice for somatic stem cell-based products. 
In these contexts, the manufacture of CTPs must generally comply with current Good 
Manufacturing Practices (or Good Tissue Practice if not classified as drugs), but their use is 
otherwise regulated as clinical practice, not research. The exception is the US, where the 
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manufacturing of biological drugs is controlled solely by the Food and Drug Administration 
(FDA), which has no such exemptions for medical practitioners to make and supply their 
own drugs. However, the FDA’s jurisdiction only applies to products, or ingredients that 
make up those products, that are shipped across state borders; the question of whether this 
authority extends to products made with ingredients sourced and delivered entirely within 
state borders, but which compete with products sold in other states, remains unresolved 
(Koustas and Fleder, 2011). Regulation of these products presumably falls under the 
jurisdiction of the medical boards and health departments in each American state.  
Structural Weaknesses and the Challenge for Regulators 
Despite the many technical differences in implementation and nomenclature, the general 
approach in all five countries is to provide a clear evidence-based pathway for CTPs that are 
regulated as medicinal drugs while allowing patients to access low-risk interventions with 
autologous ASCs under the supervision of their physician. This approach is designed to 
provide protections for research subjects while maintaining clinical autonomy for medical 
professionals and their patients. To support these goals, all five jurisdictions have 
implemented risk-based approaches to the regulation of CTPs, giving regulators a degree of 
flexibility in determining the level of oversight and standards of evidence that should apply 
before these products are introduced onto the market. However, as their use in clinical 
practice is largely unregulated, the approach also creates structural weaknesses that may be 
exploited by unscrupulous operators.  
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A key challenge that regulators face in addressing these weaknesses is ensuring that 
patients have the freedom to access novel interventions, while accommodating the inherent 
uncertainties of clinical research. Where uncertainty is a key characteristic of science – and 
regulations, ethical guidelines and governance processes can be designed to minimize 
harms that may arise from it – regulating clinical decisions in the face of such uncertainty is 
often more difficult. Across all five jurisdictions, regulators and policymakers are generally 
reluctant to interfere in decisions that many would argue should remain within the doctor-
patient relationship. Yet, while historically this has been politically and culturally acceptable, 
few would agree that physicians should be permitted carte blanche authority in their 
practice of medicine, unchecked by accountability to their patients or the social systems 
that ultimately provide their healthcare. Balancing professional and patient autonomy with 
the need to provide therapies that are evidence-based, yield a meaningful benefit and are 
affordable to the community may, therefore, create a potentially intractable problem for 
regulators and policy-makers.  
Regulators do have power to control unethical and illicit clinical practices, however, and a 
number of mechanisms may be employed to control the use of autologous ASCs outside 
clinical trials without infringing on clinical freedoms or stifling innovation in clinical care. 
Some countries have already activated these mechanisms by sanctioning offending 
practitioners. In 2010, the British General Medical Council deregistered Dr Robert Trossel for 
unjustifiably administering an allogeneic cellular preparation (also found to contain bovine 
neural cells) to patients affected by multiple sclerosis at a clinic in Rotterdam. The Singapore 
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Medical Council has previously sanctioned four of its practitioners for offering various stem 
cell products without evidence of efficacy, but has since withdrawn two following an appeal. 
Florida’s Board of Medicine has also revoked the license of Dr Zannos Grekos following the 
death of two patients following or during procedures intended for the delivery of 
autologous stem cells, which is now under appeal. These enforcement actions may not have 
deterred physicians from routinely offering unproven stem cell interventions outside clinical 
trials, at least not the US, although they are unlikely to have harmed innovative practice in 
any of these countries.  
While these actions are commendable, additional measures clearly need to be taken over 
and above the sanctioning and deregistration of individual practitioners. For instance, better 
guidance is needed to clarify the circumstances in which autologous ASCs may be 
administered to patients before sufficient evidence of safety and efficacy has been 
established in clinical trials. The Texas Medical Board (2012) has introduced rules on the 
investigational use of human stem cells that appears to provide an alternative to the IND 
pathway by allowing physicians to seek IRB approval to prescribe agents not approved by 
the FDA in their practice. These guidelines have been the subject of extensive criticism, 
principally because they appear to substitute formal regulatory oversight with IRB approval 
(Levine, 2012), even though federal manufacturing standards supersede state laws. The 
Practice Notice in Japan also attempts to provide guidance for physicians who use 
autologous cells in their practice by encouraging ethics approval.  
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Where regulators can take greater action is to enforce the existing laws that regulate the 
advertising of medicinal products. All five countries have tort laws in place for medical 
negligence and consumer protection legislation that restrict false advertising and the 
provision of misleading information in medical practice. Practitioners, healthcare providers 
and manufacturers who create websites and advertise the routine use of interventions with 
autologous ASCs that have not been established as an accepted standard of care, or provide 
misleading information about the effectiveness of such interventions, should be prosecuted 
under the relevant laws. These laws can be activated without infringing on the autonomy of 
patients or practitioners who use innovative biomedicines responsibly and in the best 
interests of those under their care.  
Conclusion 
Given our comparative analysis of regulatory frameworks in the five countries studied, it 
remains unclear why autologous ASCs are being prescribed outside clinical trials more often 
in Australia, Japan and the US, than in Singapore and the UK. Although we found technical 
differences in how key terms are defined within the regulations, and ambiguities that could 
be interpreted differently across jurisdictions, these do not sufficiently account for why the 
use of autologous ASC has proliferated in some countries and not others. All of these 
countries clearly regulate clinical practice with an emphasis on evidence-based medicine, 
while allowing clinicians to develop innovative care in a limited, responsible manner, and 
patients to access CTPs that lack the level of evidence necessary for market authorization or 
reimbursement from public and private health insurers. While this approach may support 
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research and in some cases work in the interests of patient autonomy and access to care, it 
also creates structural weaknesses that may be exploited by commercial interests who 
either willfully misinterpret ambiguous definitions in the regulation of drug research or 
ignore them altogether.  
In discouraging the exploitation of vulnerable patient populations while still allowing 
scientific and clinical innovation, relevant authorities should work together in standardizing 
the terminology and scientific processes used to define and classify CTPs as minimal risk and 
exclude them from regulation. The difficulties seen in harmonizing regulations across EU 
countries, however, suggest that standardization across diverse jurisdictions will be even 
more challenging, as key terms may still be interpreted and acted upon differently according 
to national interests and the local needs of patients. Scientific definitions and evaluations of 
risk are also contestable. Thus, the solution is unlikely to come from simply clarifying and 
standardizing nomenclature, although this could help regulators improve the transparency 
of drug designations.  
In our opinion, the structural weaknesses described above manifest in the separation of 
research regulation from clinical governance, and solutions must address how novel 
therapeutics are introduced into the practice of medicine. Safety alone is not sufficient to 
justify routine clinical use of ASCs as even low risk products should show compelling 
evidence of efficacy before they are introduced into healthcare systems and accepted as the 
standard of care. While we can activate and enforce existing consumer protection laws and 
prohibitions on false and misleading advertising in medical practice, these are post hoc 
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mechanisms where the burden is placed on adequately-resourced patients and authorities 
to demonstrate evidence of wrongdoing; and in taking such action, plaintiffs may potentially 
be exposed to counter-suits for libel. Medical authorities may also take a more proactive 
role in sanctioning practitioners whose conduct falls outside accepted professional 
standards and provide better guidance for those who want to prescribe innovative 
biomedicines responsibly before evidence of efficacy has been established in clinical trials. 
However, the impetus of these actions remains with the medical profession, and the lack of 
sanctions against practitioners who continue to prescribe autologous ASCs without evidence 
of their efficacy suggests that the self-regulatory model of clinical governance is becoming 
outdated. New models are needed to oversee the introduction of novel CTPs into clinical 
contexts in ways that acknowledge and allow for scientific uncertainties while enabling 
patient access to novel treatments and ensuring that rigorous and responsible research is 
unimpeded by commercial interests.  
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Tables 
Table 1: Agencies that regulate medicinal drug products. 
Jurisdiction Regulatory Agency Jurisdictional Laws & Regulations 
United States Food and Drug Administration (FDA) Public Health Services Act (42 USC 
§§262, 264, 271) 
Code of Federal Regulations (21 CFR 
§1271) 
Japan Ministry of Health, Labour and Welfare (MHLW)  
 
 
 
 
 
 
Pharmaceuticals & Medical Device Agency 
(PMDA) 
Medical Practitioners Law, Law No. 201 
of 1948 
Practice Notice: Conducting 
Regenerative and Cellular Medicine 
Using Autologous Cells and Tissues at 
Medical Institutions (2010) 
Regenerative Medicine Law (draft) 
Pharmaceutical Affairs Law, Law No. 
145 of 1960,as amended 
Australia Therapeutic Goods Administration (TGA) Therapeutic Goods Act 1989 and 
Regulations 1990 (Cth) 
Australian Regulatory Guidelines for 
Biologicals 
Singapore Health Sciences Authority (HSA) Medicines Act (1975, revised 1985) 
Medicines (Clinical Trials) Regulations 
(1978, revised 2000) 
Health Products Act (2007) 
United Kingdom Medicines and Healthcare Products Regulatory 
Agency (MHRA) 
 
European Medicines Agency (EMA) 
The Medicines Act (1968) 
Human Medicines Regulations 2012 (SI 
2012/1916). 
Advanced Therapy Medicinal Products 
Regulation (EC No 1394/2007) and 
Directive (2001/83/EC) 
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